4β‐hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|80|3|560-568

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.3, 2015-09, pp. : 560-568

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus Capecitabine Combination in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

By  

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 308-313

Karger

Access to resources Recommend Favorite

UFT plus Oral Folinic Acid with Alternating Oral and Intravenous Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 562-566

Karger

Access to resources Recommend Favorite

An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 6, 2018-03 ,pp. : 1218-1229

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiapoptotic and Proliferative Effects of Low Concentrations of 7β-Hydroxycholesterol in Human Endothelial Cells via ERK Activation

By  

Journal of Vascular Research, Vol. 47, Iss. 3, 2009-11 ,pp. : 241-251

Karger

Access to resources Recommend Favorite

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1378-1385

John Wiley & Sons Inc

Access to resources Recommend Favorite